Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_assertion type Assertion NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_head.
- NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_assertion description "[The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_provenance.
- NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_assertion evidence source_evidence_literature NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_provenance.
- NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_assertion SIO_000772 15948676 NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_provenance.
- NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_assertion wasDerivedFrom befree-2016 NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_provenance.
- NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_assertion wasGeneratedBy ECO_0000203 NP498850.RALNnImVcw6gJFpMFK2gSeWWceKNMiE-oI9btj5QrY1BM130_provenance.